Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
J Neuroeng Rehabil ; 21(1): 118, 2024 Jul 13.
Article de Anglais | MEDLINE | ID: mdl-39003450

RÉSUMÉ

BACKGROUND: How the joints exactly move and interact and how this reflects PD-related gait abnormalities and the response to dopaminergic treatment is poorly understood. A detailed understanding of these kinematics can inform clinical management and treatment decisions. The aim of the study was to investigate the influence of different gait speeds and medication on/off conditions on inter-joint coordination, as well as kinematic differences throughout the whole gait cycle in well characterized pwPD. METHODS: 29 controls and 29 PD patients during medication on, 8 of them also during medication off walked a straight walking path in slow, preferred and fast walking speeds. Gait data was collected using optical motion capture system. Kinematics of the hip and knee and coordinated hip-knee kinematics were evaluated using Statistical Parametric Mapping (SPM) and cyclograms (angle-angle plots). Values derived from cyclograms were compared using repeated-measures ANOVA for within group, and ttest for between group comparisons. RESULTS: PD gait differed from controls mainly by lower knee range of motion (ROM). Adaptation to gait speed in PD was mainly achieved by increasing hip ROM. Regularity of gait was worse in PD but only during preferred speed. The ratios of different speed cyclograms were smaller in the PD groups. SPM analyses revealed that PD participants had smaller hip and knee angles during the swing phase, and PD participants reached peak hip flexion later than controls. Withdrawal of medication showed an exacerbation of only a few parameters. CONCLUSIONS: Our findings demonstrate the potential of granular kinematic analyses, including > 1 joint, for disease and treatment monitoring in PD. Our approach can be extended to further mobility-limiting conditions and other joint combinations. TRIAL REGISTRATION: The study is registered in the German Clinical Trials Register (DRKS00022998, registered on 04 Sep 2020).


Sujet(s)
Agents dopaminergiques , Maladie de Parkinson , Amplitude articulaire , Humains , Maladie de Parkinson/traitement médicamenteux , Maladie de Parkinson/physiopathologie , Mâle , Femelle , Études cas-témoins , Phénomènes biomécaniques , Adulte d'âge moyen , Sujet âgé , Agents dopaminergiques/usage thérapeutique , Amplitude articulaire/physiologie , Articulation du genou/physiopathologie , Démarche/physiologie , Démarche/effets des médicaments et des substances chimiques , Articulation de la hanche/physiopathologie , Troubles neurologiques de la marche/physiopathologie , Troubles neurologiques de la marche/traitement médicamenteux , Troubles neurologiques de la marche/étiologie , Articulations/physiopathologie
2.
Sleep Med ; 118: 71-77, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38613859

RÉSUMÉ

BACKGROUND: Multiple Sclerosis (MS) is a chronic inflammatory autoimmune, neurodegenerative disease that affects regular mobility and leads predominantly to physical disability. Poor sleep quality, commonly reported in MS patients, impacts their physical activity (PA). Accelerometers monitor 24-h activity patterns, offering insights into disease progression in daily life. OBJECTIVE: To test if the sleep quality variables of MS patients, as assessed with wrist-worn accelerometers, differ from those of controls and are associated with PA and disease severity variables. METHODS: Seven-day raw accelerometer data collected from 40 MS patients and 24 controls was processed using an open-source GGIR package, from which variables of sleep quality (sleep efficiency, wake after sleep onset (WASO), sleep regularity index (SRI), intradaily variability (IV)) and PA (of different intensities: inactivity, light (LPA), moderate (MPA), vigorous (VPA)) were analyzed. The variables were compared between the two study groups and in MS patients, correlation tested associations among the variables of sleep quality, PA, and disease severity (assessed with the Expanded Disability Status Scale, EDSS). RESULTS: Sleep efficiency was the only variable that differed significantly between MS patients and controls (lower in MS, p = 0.01). Both SRI (positively) and IV (negatively) correlated with the time spent in LPA and MPA. WASO correlated negatively with inactivity. CONCLUSION: This is one of the few studies with a wrist-worn accelerometer that shows a difference in sleep efficiency between MS patients and controls and, in MS, an association of sleep quality variables with PA variables.


Sujet(s)
Accélérométrie , Exercice physique , Sclérose en plaques , Indice de gravité de la maladie , Qualité du sommeil , Humains , Femelle , Mâle , Exercice physique/physiologie , Sclérose en plaques/complications , Sclérose en plaques/physiopathologie , Accélérométrie/instrumentation , Adulte , Adulte d'âge moyen
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE